Business Context and Reporting Period
The supplied filing is a Form 10-Q for Brooks Automation, Inc., not Azenta, Inc. It covers the quarter and six months ended March 31, 2013, within fiscal 2013. Brooks provided automation, vacuum, instrumentation, global services, and life-science systems, with approximately 47% of first-half fiscal 2013 revenue from semiconductor-related markets.
Financial Highlights
| Metric | Three Months Ended March 31, 2013 | Prior Year | Six Months Ended March 31, 2013 | Prior Year |
|---|---|---|---|---|
| Revenue | $116.6 million | $139.3 million | $214.6 million | $259.6 million |
| Gross profit | $36.6 million | $48.3 million | $65.8 million | $88.6 million |
| Gross margin | 31.4% | 34.7% | 30.6% | 34.1% |
| Operating income (loss) | $(1.0) million | $8.4 million | $(14.0) million | $9.9 million |
| Net income (loss) attributable to Brooks | $(0.5) million | $9.7 million | $(9.8) million | $12.5 million |
| Diluted EPS | $(0.01) | $0.15 | $(0.15) | $0.19 |
| Operating cash flow | Not separately provided | Not separately provided | $16.7 million | $21.7 million |
| Adjusted EBITDA | $9.2 million | $20.9 million | $12.4 million | $31.5 million |
At March 31, 2013, cash and cash equivalents were $60.1 million, and total marketable securities were $85.5 million, for aggregate cash, cash equivalents, and marketable securities of approximately $145.6 million. The filing reports no material debt balance; total liabilities were $94.5 million, including $81.5 million of current liabilities. The company had approximately $2.5 million of letters of credit outstanding.
Total assets were $721.8 million and shareholders’ equity was $627.3 million at March 31, 2013. Accounts receivable were $73.5 million and inventories were $96.6 million.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue declined 16%; first-half revenue declined 17%, primarily because of weaker semiconductor capital-equipment demand and lower life-science sales.
- Brooks Product Solutions revenue declined 17% in the quarter and 22% year to date. Brooks Life Science Systems revenue declined 38% in the quarter and 15% year to date.
- Brooks Global Services revenue increased 4% in the quarter but was approximately flat for the six-month period, with acquisition-related revenue offsetting underlying weakness.
- Gross margin declined 330 basis points in the quarter and 350 basis points year to date because of lower production volumes, reduced fixed-cost absorption, Crossing purchase-accounting charges, and higher intangible amortization.
- The company recorded $0.8 million of restructuring charges in the quarter and $5.5 million year to date, compared with $42,000 and $245,000, respectively, in the prior-year periods.
- The company acquired Crossing Automation on October 29, 2012, for $59.0 million net of cash acquired. Crossing contributed $12.2 million of quarterly revenue and $20.7 million of first-half revenue, but generated losses of $0.6 million and $2.5 million, respectively, including inventory step-up and amortization charges.
- Cash from operations decreased to $16.7 million from $21.7 million, while cash and cash equivalents increased $5.5 million from September 30, 2012, largely because of marketable-security sales.
- The company’s accumulated deficit increased to $1.013 billion from $992.5 million at September 30, 2012.
Guidance, Outlook, Risks, and Unusual Items
- Management expected moderately higher near-term revenue from semiconductor capital-equipment customers based on recent customer communications.
- Management expected the recent decline in the life-science business to recover by fiscal year-end, but warned that a slower recovery could require impairment of related goodwill or long-lived assets.
- Restructuring actions were expected to be substantially completed before June 30, 2013. Management estimated approximately $23.0 million of annualized cost-structure savings, including approximately $4.0 million from reduced temporary staffing.
- The company outsourced manufacturing of its Polycold product line. The total related severance and retention cost was expected to be $1.3 million, with $0.6 million expensed by March 31, 2013.
- Management believed available resources were sufficient for planned working capital and capital expenditures for the next twelve months, while noting that semiconductor cyclicality and the global economic environment make longer-term liquidity needs difficult to predict.
- The company paid $10.7 million in dividends during the first six months and declared an additional $0.08-per-share dividend, approximately $5.3 million, payable June 28, 2013. Future dividends remained discretionary and could be reduced, delayed, or canceled.
- Foreign-currency exposure remained material: 26% of first-half sales were in currencies other than the U.S. dollar, and a hypothetical 10% exchange-rate change was estimated to affect net income by approximately $0.9 million.
- Legal proceedings arose in the ordinary course of business. Management did not expect them to have a material adverse effect, but acknowledged that outcomes were uncertain.
- Income-tax benefits were $0.1 million for the quarter and $3.8 million year to date. The company maintained valuation allowances against certain U.S. tax credits, state net operating losses, and tax attributes in jurisdictions without cumulative profitability.
Most Important Facts for Investors to Verify
- Confirm that the intended issuer is Brooks Automation rather than Azenta, Inc.; the supplied filing predates the Azenta name.
- Assess whether semiconductor demand improved as management expected and whether life-science sales recovered by fiscal year-end.
- Evaluate Crossing Automation’s continuing revenue contribution, profitability, integration progress, and expected synergies.
- Verify realization of the estimated $23.0 million cost savings and the cash costs remaining under the restructuring plan.
- Monitor gross-margin recovery after purchase-accounting charges, lower utilization, and Polycold manufacturing outsourcing.
- Review liquidity after the acquisition, dividends, restructuring payments, and any future capital requirements.
- Assess potential goodwill and long-lived-asset impairment risk in the Life Science Systems segment.
- Review customer concentration, including one customer representing 13% of quarterly revenue and 11% of first-half revenue.